Nature Cell’s Stem Cell Alzheimer’s Therapy Advances Amid Failures
Nature Cell is set to begin a groundbreaking clinical trial in the US of a novel autologous stem cell therapy for Alzheimer's disease, a new approach likely to gain attention amid other high profile failures in the challenging indication.
You may also be interested in...
While the company is hyping the benefit seen in a subgroup analysis of the first Phase III trial of the tau aggregation inhibitor, which failed to show an overall benefit in mild-to-moderate Alzheimer's disease, Datamonitor Healthcare analyst Maha Elsayed raises some questions.
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.